

A dedicated microarray for in-depth analysis of pre-mRNA splicing events: application to the study of genes involved in the response to targeted anticancer therapies

Marine Pesson, Béatrice Eymin, Pierre de la Grange, Brigitte Simon, Laurent Corcos

► **To cite this version:**

Marine Pesson, Béatrice Eymin, Pierre de la Grange, Brigitte Simon, Laurent Corcos. A dedicated microarray for in-depth analysis of pre-mRNA splicing events: application to the study of genes involved in the response to targeted anticancer therapies. *Molecular Cancer*, BioMed Central, 2014, 13 (9), 10.1186/1476-4598-13-9 . inserm-02337442

HAL Id: inserm-02337442

<https://www.hal.inserm.fr/inserm-02337442>

Submitted on 29 Oct 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

RESEARCH

Open Access

A dedicated microarray for in-depth analysis of pre-mRNA splicing events: application to the study of genes involved in the response to targeted anticancer therapies

Marine Pesson¹, Béatrice Eymin², Pierre De La Grange³, Brigitte Simon¹ and Laurent Corcos^{1*}

Abstract

Alternative pre-mRNA splicing (AS) widely expands proteome diversity through the combinatorial assembly of exons. The analysis of AS on a large scale, by using splice-sensitive microarrays, is a highly efficient method to detect the majority of known and predicted alternative transcripts for a given gene. The response to targeted anticancer therapies cannot easily be anticipated without prior knowledge of the expression, by the tumor, of target proteins or genes. To analyze, in depth, transcript structure and levels for genes involved in these responses, including *AKT1-3*, *HER1-4*, *HIF1A*, *PIK3CA*, *PIK3R1-2*, *VEGFA-D* and *PIR*, we engineered a dedicated gene chip with coverage of an average 185 probes per gene and, especially, exon-exon junction probes. As a proof of concept, we demonstrated the ability of such a chip to detect the effects of over-expressed SRSF2 RNA binding protein on the structure and abundance of mRNA products in H358 lung cancer cells conditionally over-expressing SRSF2. Major splicing changes were observed, including in *HER1/EGFR* pre-mRNA, which were also seen in human lung cancer samples over-expressing the SRSF2 protein. In addition, we showed that variations in *HER1/EGFR* pre-mRNA splicing triggered by SRSF2 overexpression in H358 cells resulted in a drop in HER1/EGFR protein level, which correlated with increased sensitivity to gefitinib, an EGFR tyrosine kinase inhibitor. We propose, therefore, that this novel tool could be especially relevant for clinical applications, with the aim to predict the response before treatment.

Keywords: DNA chip, Targeted anticancer therapies, Pre-mRNA splicing, SRSF2

Background

Alternative pre-mRNA splicing (AS) occurs for an estimated 90% of genes in the human genome [1], with remarkable repercussions on proteome diversity [2]. The outcome of AS strongly depends on context. Hence, AS occurs to allow the onset of development or differentiation programs, to participate in cancer occurrence or progression, and to develop integrated responses to stressful conditions [3-5]. Importantly, AS transcripts may encode alternative protein isoforms, which quite often display distinct or even opposite functions, such as for the pro- or anti-apoptotic caspases or Bcl-2 family proteins [6-8]. In addition, AS may also lead to the assembly of

short-lived mRNAs targeted to degradation through the nonsense mediated decay (NMD) system [9]. However, even if NMD transcripts do not encode proteins, their occurrence may modify the ratio of mRNA isoforms, potentially affecting protein synthesis outcome [10].

Analytical tools to study AS on a large scale have been developed by Affymetrix™, with the Human Exon 1.0 ST arrays, also referred to as splice-sensitive microarrays, which allow surveying known and predicted AS events throughout the transcriptome [11,12]. Recently, deep sequencing methods have made it possible to determine both mRNA levels and structure [13-15]. Nevertheless, the mathematical tools necessary to decipher the structure and amount of mRNA species identified by sequencing are still under constant development [16,17]. In addition, a recent comparison between RNA-Seq and Affymetrix™ Exon arrays has revealed that the chip method was more

* Correspondence: laurent.corcos@inserm.fr

¹UMR INSERM U1078-UBO, Equipe ECLA, Faculté de Médecine, 22 Avenue Camille Desmoulins, 29200 Brest, France

Full list of author information is available at the end of the article

powerful at detecting and quantifying exons [18]. It was also demonstrated that microarray technologies could be used as a reliable routine diagnostic tool, thanks to the development of a small custom-made microarray able to predict disease outcome in breast cancer patients [19]. Following on that path, the aim of the present study was to develop a customized microarray enabling to detect both known and predictable AS events for a small number of genes involved in tumor growth and in the response to targeted anticancer therapies. To take advantage of the DNA chip experimental setup, we wished to improve the methodology by increasing the amount of probes, including exon-exon junction probes absent from Affymetrix™ Exon arrays, which would allow detecting virtually all AS events that could occur in this subset of genes.

Targeted anticancer therapies include drugs, such as inhibitors of tyrosine kinase or monoclonal antibodies (mAbs), which oppose cell growth signaling or tumor blood vessel development, promote the specific death of cancer cells, or stimulate the immune system. Among specific molecules with which targeted therapies interfere, the HER (human epidermal growth factor receptor) family regulates cell growth, survival, adhesion, migration and differentiation. Trastuzumab (Herceptin™), which was FDA-approved in 2000, was the first treatment using a humanized mAb to target the receptor tyrosine kinase encoded by the *HER2* oncogene, and is mainly used to treat breast cancers over-expressing this receptor [20,21]. Cetuximab (Erbix™) and gefitinib (Iressa™) target HER1/EGFR (epithelial growth factor receptor), or its tyrosine kinase activity, respectively, and bevacizumab (Avastin™) blunts VEGF-A (vascular endothelial growth factor A) activity upon binding to the Gly88 residue from the extracellular domain [22]. AS transcript variants have been characterized for all these targets, especially for *VEGFA* [23-25], and could account for part of the inefficacy of the responses to mAbs. The PIK3/Akt pathway is a major signaling cascade downstream of the receptor tyrosine kinases. In addition, *VEGFA* expression is regulated by the hypoxia factor HIF-1 α . The analyzed genes on this custom microarray include *AKT1-3*, *HER1-4*, *HIF1A*, *PIK3CA*, *PIK3R1-2*, *VEGFA-D*, and *PIR* that lies close to the *VEGFD* locus and could be fused to *VEGFD* upon read through transcription. Collectively, these genes can lead to the assembly of more than 100 mRNAs with protein-coding capacity (<http://www.ensembl.org>). Hence, the response to targeted anticancer therapy will likely depend, at least in part, on the selection of specific combinations of protein targets derived from AS events.

In order to validate our custom DNA chip, we took advantage of the human lung adenocarcinoma H358 cell line that we previously engineered to conditionally over-express the pre-mRNA splicing enhancer protein SRSF2, which controls the splicing of *VEGFA* pre-mRNA [26], but

also has a role in transcriptional elongation [27]. Positive results were further validated by specific quantitative RT-PCR in both H358 cells and human non-small cell lung carcinoma (NSCLC) samples that we previously showed to over-express the SRSF2 protein [28]. The repercussion of altered splicing on the amount of the HER1/EGFR protein and the response to gefitinib were analyzed in H358 cells.

Results

Validation of the splice-inducing ability of SRSF2

Using an E1A-based plasmid minigene in transient transfection experiments, we analyzed the splice-inducing ability of SRSF2 (Additional file 1: Figure S1). There was an up-regulation of the 13S PCR band associated with a down-regulation of the 9S band, indicating that SRSF2 over-expression could modify the balance of E1A-derived transcripts, as originally described [29].

Cross validation with 44 k Agilent microarray

To analyze the gene expression changes triggered by over-expression of SRSF2 in H358 lung cancer cells, we performed an analysis using 44 k Agilent™ microarrays. These data have been deposited in NCBI's Gene Expression Omnibus and are accessible through GEO Series accession number GSE50467. A lot of genes were differentially expressed between SRSF2-over-expressing H358 lung cancer cells and H358 control cells (1,709 deregulated probes; ≥ 2.0 FC, P-value ≤ 0.05 by *t*-test with FDR; Additional file 2: Table S1), corresponding to 52% up- and 48% down-regulations. Hence, in addition to its already reported role in the regulation of *VEGFA* splicing, over-expression of SRSF2 led to the regulation of transcript abundance of many additional genes, including genes present on the 15 k custom chip (Additional file 3: Table S2), as demonstrated with the 44 k Agilent™ microarrays.

Validation of the labeling method: comparison of the 15 k custom and 44 k Agilent microarrays

The labeled cRNA yield and the specific activity of cyanine3 were examined for each of three labeling experiments (Additional file 4: Table S3). A comparison of the 15 k custom and 44 k commercial microarrays, with respect to Agilent™ probes present on both chips, was performed in order to validate the use of the labeling method with the 15 k custom microarray. The number of 15 k replicates using Quick Amp labeling was equal to 4 for each condition (control or SRSF2 over-expression), and the number of 44 k replicates was equal to 6 for each condition. We found that 313 Agilent™ probes (corresponding to 16% of the total number of Agilent™ probes on the 15 k chip) were deregulated on the 15 k custom microarray (≥ 1.5 FC, P-value ≤ 0.05), among which 310 (99%) had the same type of (up- or down-) regulation on the 44 k

commercial microarrays (Additional file 5: Table S4). Pearson correlation between expression signals of these 313 common genes led to a coefficient of 0.89. Therefore, it was considered that Quick Amp labeling was validated for the 15 k custom microarray.

Detection of the mRNA regulation

We analyzed the expression of the 16 selected genes present in the 15 k custom microarray, considering the expression of all custom probes for each gene (Table 1). Four genes (*HER4*, *PIK3CA*, *PIK3R1* and *VEGFD*) were not expressed; five genes (*AKT2*, *AKT3*, *HER2*, *PIK3R2* and *VEGFC*) were not differentially expressed; five genes (*AKT1*, *HER3*, *HIF1A*, *PIR* and *VEGFB*) were slightly down-regulated (≤ 1.5 FC, $P\text{-value} \leq 0.05$); *HER1/EGFR* was more strongly down-regulated (≥ 1.5 FC, $P\text{-value} \leq 0.05$), and *VEGFA* was up-regulated (≥ 1.5 FC, $P\text{-value} \leq 0.05$) in SRSF2-over-expressing H358 lung cancer cells in comparison to H358 control cells. A good concordance between the 15 k and 44 k microarray results was found: 8 out of the 16 genes present in 15 k custom chip were deregulated on 44 k chips (≥ 1.1 FC, $P\text{-value} \leq 0.05$), considering Agilent™ probes, and showed the same type of regulation on the 15 k chip, considering custom probes (Additional file 3: Table S2).

Regulation events among the expressed genes

The bioinformatics analysis of the 15 k custom microarray showed that 30 custom probe sets from expressed genes

were differentially expressed in SRSF2-over-expressing H358 lung cancer cells in comparison to H358 control cells (≥ 1.5 FC, $P\text{-value} \leq 0.05$; Table 2). The low expressed deregulated probe sets were not considered. The regulation events corresponded to 70% down- and 30% up-regulations, mostly affecting cassette exons, but also 5'-untranslated regions and terminal or donor splice sites, of 9 genes among the 12 expressed genes (*AKT2*, *AKT3*, *HER1/EGFR*, *HER2*, *HER3*, *HIF1A*, *PIK3R2*, *VEGFA* and *VEGFB*). Regulations were associated with a high, medium or low confidence, depending on the regulation of probes close to the deregulated probe sets. A list of supporting evidences (Additional file 6: Table S5) was defined corresponding to the regulations that were not always statistically relevant, but confirmed the deregulation of some probe sets. Consequently, these regulations were associated with a high confidence. On the contrary, the confidence was considered as low if neighboring probes were not deregulated or if their regulation was opposite. The regulations associated with a high fold-change and corresponding to unknown and predicted pre-mRNA splicing events could be of special interest.

Validation of regulation events by real-time polymerase chain reaction

Quantitative RT-PCR was used to measure the expression of 9 genes deregulated on both the 15 k custom and the 44 k commercial microarrays, and the differential expression of all genes in SRSF2-over-expressing H358 lung

Table 1 Gene expression changes in SRSF2-over-expressing H358 lung adenocarcinoma cells

Gene regulation	Gene symbol	Control condition intensity	SRSF2 condition intensity	Regulation	Fold-change	P-value
Up-regulated	<i>VEGFA</i>	9.25	9.99	up	1.67	3.38E-08
Down-regulated	<i>HER1/EGFR</i>	5.01	4.11	down	1.87	3.65E-06
Slightly down-regulated	<i>HER3</i>	2.33	1.78	down	1.47	3.98E-03
	<i>HIF1A</i>	6.48	6.06	down	1.33	2.04E-04
	<i>PIR</i>	7.01	6.62	down	1.32	1.82E-03
	<i>AKT1</i>	8.04	7.68	down	1.28	8.15E-05
	<i>VEGFB</i>	7.84	7.48	down	1.28	2.56E-04
Not regulated	<i>PIK3R2</i>	3.94	4.19	up	1.19	1.62E-01
	<i>AKT3</i>	2.00	1.91	down	1.06	6.18E-01
	<i>HER2</i>	4.89	4.81	down	1.05	4.01E-01
	<i>AKT2</i>	5.81	5.74	down	1.05	5.57E-01
	<i>VEGFC</i>	5.90	5.89	down	1.01	9.03E-01
Not expressed	<i>PIK3R1</i>	1.35	1.89	up	1.45	3.71E-02
	<i>VEGFD</i>	0.88	0.98	up	1.07	8.23E-02
	<i>HER4</i>	0.65	0.69	up	1.03	4.87E-01
	<i>PIK3CA</i>	1.79	1.78	down	1.01	8.58E-01

The expression and the regulation of the 16 genes were analyzed on the 15 k custom microarray in SRSF2-over-expressing H358 lung cancer cells in comparison to control cells. Some genes were not expressed; others were not differentially expressed. Five genes were slightly down-regulated (≤ 1.5 FC, $P\text{-value} \leq 0.05$), and one gene (*HER1/EGFR*) was more strongly down-regulated (≥ 1.5 FC, $P\text{-value} \leq 0.05$). Only one gene (*VEGFA*) was up-regulated in the SRSF2 over-expression condition (≥ 1.5 FC, $P\text{-value} \leq 0.05$).


Table 2 Deregulated probe sets in SRSF2-over-expressing H358 lung adenocarcinoma cells

Gene symbol	Region name	Region type	Confidence	Regulation	Fold-change	P-value	RT-PCR
<i>AKT2</i>	je14_e15_5p_region	Junction	Low	Down	1.63	1.36E-02	No
<i>AKT3</i>	je7_e8	Junction	High	Down	5.99	2.07E-05	Yes
<i>AKT3</i>	e8	Exon	High	Down	4.19	4.10E-03	Yes
<i>HER1/EGFR</i>	je16_e19	Junction	High	Down	3.66	1.42E-03	Yes
<i>HER1/EGFR</i>	predict_exon_1_2-10	Exon	Medium	Up	33.98	0.00E+00	No
<i>HER1/EGFR</i>	est_1_2	Exon	Medium	Up	17.35	1.00E-09	No
<i>HER1/EGFR</i>	predict_exon_2_3-1	Exon	Medium	Up	4.97	5.51E-05	No
<i>HER1/EGFR</i>	e26	Exon	Medium	Down	2.64	2.30E-03	No
<i>HER1/EGFR</i>	ae1_donor_alter	Donor_alter	Medium	Up	5.55	5.40E-03	No
<i>HER1/EGFR</i>	je14_e15	Junction	Low	Down	1.87	1.05E-02	No
<i>HER1/EGFR</i>	je12_e13	Junction	Low	Down	1.76	1.13E-02	No
<i>HER2</i>	ae10_prom_alter	Prom_alter	Medium	Down	2.73	2.32E-02	No
<i>HER3</i>	je22_ae23_acceptor_alter_l	Junction	Low	Up	1.68	3.33E-02	No
<i>HIF1A</i>	je10_e11	junction	High	Down	1.87	1.66E-05	Yes
<i>HIF1A</i>	e10	Exon	High	Down	1.62	3.65E-02	Yes
<i>HIF1A</i>	e9	Exon	High	Down	1.56	4.78E-02	Yes
<i>HIF1A</i>	e5	Exon	Low	Down	2.07	1.23E-02	No
<i>HIF1A</i>	je1_5p_region_ae3_acceptor_alter	Junction	Low	Down	1.56	1.64E-02	No
<i>HIF1A</i>	je14_e16	Junction	Low	Up	2.22	2.08E-02	No
<i>PIK3R2</i>	e6	Exon	High	Down	1.97	7.61E-05	No
<i>PIK3R2</i>	je5_e6	Junction	High	Down	3.95	3.98E-04	No
<i>PIK3R2</i>	je7_e8	Junction	Low	Down	1.68	2.14E-03	No
<i>PIK3R2</i>	e9	Exon	Low	Down	1.74	3.34E-03	No
<i>PIK3R2</i>	je2_e3	Junction	Low	Down	1.58	4.36E-02	No
<i>VEGFA</i>	e4_term_alter	Term_alter	High	Up	10.18	7.43E-08	Yes
<i>VEGFA</i>	ae6_donor_alter_2	Donor_alter	High	Down	2.44	4.18E-07	Yes
<i>VEGFA</i>	jae6_donor_alter_2_e7	Junction	High	Down	1.93	4.96E-03	Yes
<i>VEGFA</i>	ae7_donor_alter	Donor_alter	High	Up	1.80	6.98E-04	Yes
<i>VEGFA</i>	e7	Exon	Low	Up	1.50	4.00E-04	No
<i>VEGFB</i>	je2_e3	Junction	Low	Down	1.62	6.47E-05	No

A list of the 30 differentially expressed and deregulated custom probe sets (≥ 1.5 FC, P -value ≤ 0.05) from expressed genes among the 16 analyzed genes in SRSF2-over-expressing lung cancer cells in comparison to control cells on the 15 k custom microarray is presented. The regulations were associated with a high, medium or low confidence, depending on the regulation of probes in the vicinity of the deregulated probe sets. According to the results with a high confidence (in bold characters), we expect an up-regulation of exon 7 and a down-regulation of exon 8 for *AKT3*, a multiple exon skipping for *HER1/EGFR*, a skipping of both exons 9 and 10 for *HIF1A*, an alternative polyadenylation in intron 4, and alternative donor sites for exons 6 and 7 for *VEGFA*.

cancer cells in comparison to H358 control cells was analyzed with RNA isolated independently from that used for chip hybridization (Additional file 7: Table S6). These results confirmed the validity of our experimental approach used to analyze the 15 k custom microarray. Ten out of the 30 deregulated probe sets were selected according to their high confidence (Table 2), and concerned 4 genes, including *AKT3*, *HER1/EGFR*, *HIF1A* and *VEGFA* (Figure 1). The results of quantitative RT-PCR experiments are shown in Table 3. Relative mRNA levels were normalized to control gene mRNA levels or a fold-change was calculated comparing to a reference event. For *HER1/*

EGFR, we showed a down-regulation of one of the transcripts (last exon > e20) in SRSF2-over-expressing H358 lung cancer cells in comparison to H358 control cells. For *AKT3*, we validated the up-regulation of exon 7 and the down-regulation of exon 8; that is because the e7+/e8- transcript was over-expressed as compared to the e7+/e8+ transcript including both exons. For *HIF1A*, the up-regulation for two (e9+/e10- and e9-/e10-) of the three alternative transcripts compared to the e9+/e10+ transcript led us to conclude that both exons 9 and 10 were down-regulated. For *VEGFA*, we validated the alternative polyadenylation in intron 4 by an over-expression of the smaller



transcript (last exon = e4) in comparison to the longer transcript (last exon > e5). We also confirmed the alternative donor site for the exon 6 by an up-regulation of the “alternative donor e6” transcript in comparison with the “constitutive donor e6” transcript.

HER1/EGFR protein expression analysis

The 15 k custom microarray predicted multiple exon skipping in the 3' region of *HER1/EGFR* in SRSF2-over-expressing H358 lung cancer cells, which was confirmed by quantitative RT-PCR. These observations led us to test whether these splicing events would have an impact on the amount of the HER1/EGFR protein. Western blotting analysis was performed using various anti-EGFR antibodies directed against the N-terminal (31G7) or the C-terminal (D38B1) portion of the protein, as well as against the phosphorylated active form of EGFR (P-HER1/EGFR-Tyr1068). The results demonstrated that SRSF2

overexpression in H358 cells led to a decrease in EGFR protein amount, as detected using all antibodies (Figure 2). These data suggested that SRSF2-regulated *EGFR* pre-mRNA splicing strongly affects EGFR protein expression.

In addition, H358 cells express a wild-type EGFR protein and are resistant to apoptosis in response to EGFR tyrosine kinase inhibitors such as gefitinib. In order to determine if SRSF2-induced EGFR protein down-regulation could modify the response of H358 cells to gefitinib, we performed a dose–response of the drug in the presence or absence of SRSF2 induction (Figure 3). As expected, a 24 hours-treatment with gefitinib significantly prevented EGFR-Tyr1068 phosphorylation in these cells, but only partially engaged apoptosis at the higher concentration, which was detected by poly-ADP ribose polymerase (PARP) processing. However, caspase-3 was never activated in gefitinib-treated cells. Of note, at the highest gefitinib concentration, a reduction in the amount of total


Table 3 Quantitative RT-PCR validation in SRSF2-over-expressing H358 lung adenocarcinoma cells

SRSF2 Condition vs. Control condition					
Gene	Calculation	Transcript	Expression	Observed transcript regulation	Expected transcript regulation
HER1/EGFR	Relative expression	Last exon = e17	n/a	Not expressed	No expression
		Last exon = e18	0.91	Not regulated	Over-expression
		Last exon > e20	0.42	Under-expressed	Under-expression
AKT3	Fold-change	e7+ e8- vs. e7+ e8+	1.46	Over-expression of e7+ e8-	Over-expression of exon 7 and under-expression of exon 8
		e7- e8+ vs. e7+ e8+	-1.19	No regulation of e7- e8+	
		e7- e8- vs. e7+ e8+	n/a	No expression of e7- e8-	
HIF1A	Fold-change	e9+ e10- vs. e9+ e10+	1.91	Over-expression of e9+ e10-	Under-expression of exon 10
		e9- e10+ vs. e9+ e10+	-1.52	Under-expression of e9- e10+	Under-expression of exon 10
		e9- e10- vs. e9+ e10+	1.82	Over-expression of e9- e10-	Under-expression of exons 9 and 10
VEGFA	Fold-change	Last exon = e4 vs. last exon > e5	18.93	Over-expression of "last exon = e4"	Over-expression of exon 4
VEGFA	Fold-change	Alternative vs. constitutive donor e6	14.46	Over-expression of "alternative donor e6"	Over-expression of alternative donor


The regulation of the 10 selected deregulated custom probe sets was analyzed by quantitative RT-PCR in SRSF2-over-expressing lung cancer cells in comparison to control cells. Relative mRNA levels were normalized to that of *beta*-2-microglobulin or a fold-change was calculated comparing to a reference event. The cut-off value was equal to 1.40. n/a: not available.

EGFR together with the appearance of protein bands of smaller sizes was observed when using the 31G7 antibody mainly. These data suggested that EGFR could be processed in response to high gefitinib doses. Importantly, when SRSF2 was overexpressed in gefitinib-treated cells,

the decrease in EGFR protein amount was more pronounced and apoptosis was strongly engaged, as evidenced by procaspase-3 and PARP cleavages (Figure 3). This result indicated that SRSF2, through its ability to control EGFR protein expression, sensitizes H358 cells to the apoptosis induced by EGFR tyrosine kinase inhibitors.



Alternative splicing events in lung cancer biopsy samples
 Finally, we aimed at extending some of our *in vitro* data to cancer tissues. For this purpose, we took advantage of



the cancer-associated over-expression of SRSF2, as it may occur in NSCLC [28]. SRSF2 and phospho-SRSF2 expression scores (0–300) were established in 10 NSCLC biopsy samples (Table 4A) by multiplying the percentage of labeled tumor cells (0 to 100%) by the staining intensity (0, null; 1, low; 2, moderate; 3, strong). Interestingly, the three NSCLC samples with the highest SRSF2 and phospho-SRSF2 scores all displayed a drop in the *HER1/EGFR* “last exon > e20” transcript, as determined by quantitative RT-PCR, similarly to what occurred in lung cancer cells. We also analyzed the occurrence of the *AKT3*, *HIF1A* and *VEGFA* splicing events in NSCLC biopsy samples (Table 4B). For several samples, we observed an over-expression of exon 7 and an under-expression of exon 8 of *AKT3*, and an over-expression of exon 4 and alternative exon 6 donor splice site for *VEGFA*. Although the relationships between SRSF2 status and these splicing events were less clear in these cases, maybe owing to the small

number of samples, these data validated, in cancer samples, some of the pre-mRNA splicing events detected in the SRSF2-over-expressing H538 cell line. The results were inconclusive for *HIF1A*, possibly reflecting heterogeneity among the NSCLC samples with respect to expression of this gene.

Discussion

In this study, we designed a custom gene expression microarray amenable to the study of alternative pre-mRNA splicing (AS) events of a selection of genes involved in the response to targeted anticancer therapies. This approach was preferred to commercial microarrays, such as the Human Exon 1.0 ST arrays (Affymetrix™) because it allowed a deeper analysis of AS, in this case of a small number of genes highly relevant from a clinical standpoint. Indeed, it is clear that our custom splice-sensitive microarray could theoretically detect many more events than Affymetrix™

Table 4 Quantitative RT-PCR validation in non small cell lung carcinoma samples

A													
Sample	1	2	3	4	5	6	7	8	9	10			
SRSF2 Protein Score	270	270	240	180	160	140	120	100	60	n/a			
Phospho-SRSF2 Protein Score	270	270	270	100	100	90	60	100	40	n/a			
B													
Non small cell lung carcinoma vs. normal lung tissue													
Gene	Calculation	Transcript	1	2	3	4	5	6	7	8	9	10	Observed Transcript Regulation
<i>HER1/EGFR</i>	Relative expression	Last exon = e17	n/a	n/a	n/a	n/a	7.17	n/a	n/a	16.15	2.52	n/a	Not expressed or over-expressed
		Last exon = e18	2.69	n/a	1.86	2.27	5.13	6.86	2.23	15.16	3.01	66.18	Over-expressed
		Last exon > e20	0.15	0.29	0.20	6.71	6.99	21.45	0.10	5.39	2.46	n/a	Over-expressed or under-expressed
<i>AKT3</i>	Fold-change	e7+ e8- vs. e7+ e8+	0.84	1.46	1.16	1.37	1.08	1.76	1.29	1.47	1.47	2.28	Over-expression or no regulation
		e7- e8+ vs. e7+ e8+	n/a	1.33	n/a	1.35	n/a	n/a	n/a	0.38	n/a	n/a	Low expression of e7- e8+
		e7- e8- vs. e7+ e8+	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
<i>HIF1A</i>	Fold-change	e9+ e10- vs. e9+ e10+	0.63	0.54	1.63	1.40	0.79	1.77	0.87	1.22	1.20	1.15	Depending on biopsy samples
		e9- e10+ vs. e9+ e10+	1.87	n/a	n/a	1.06	n/a	n/a	n/a	n/a	1.14	1.77	Depending on biopsy samples
		e9- e10- vs. e9+ e10+	0.57	0.73	1.55	1.49	0.84	1.88	0.79	1.99	0.76	1.01	Depending on biopsy samples
<i>VEGFA</i>	Fold-change	Last exon = e4 vs. Last exon > e5	1.33	1.21	1.54	1.92	0.84	2.22	10.37	2.73	1.21	1.09	Over-expression or no regulation
<i>VEGFA</i>	Fold-change	Alternative vs. constitutive donor e6	3.50	3.33	5.25	3.99	n/a	n/a	19.22	14.29	n/a	45.68	Over-expression

The regulation of the 10 selected deregulated custom probe sets was analysed by quantitative RT-PCR in 10 non small cell lung carcinoma – normal sample pairs (patients numbered from 1 to 10). SRSF2 protein expression levels in biopsy samples were analysed by immunohistochemistry in a previous study. A score (0–300) was established for SRSF2 and phosphorylated SRSF2 (P-SRSF2). Patients with scores ≥ 150 and > 175 were those over-expressing SRSF2 and P-SRSF2 proteins respectively, as compared to normal lung tissues. Patients in bold characters over-expressed both proteins. n/a: not available. Relative mRNA levels were normalised to that of *beta-2-microglobulin* or a fold-change was calculated comparing to a reference event. The cut-off value was equal to 1.40. n/a: not available. Patients in bold characters over-expressed both SRSF2 and phospho-SRSF2 proteins (see Table 4A).

Exon Arrays (Table 5), considering probe length, probe number and, especially, exon-exon junction probes, which were not present on Affymetrix™ Exon Arrays. At a practical level, several high confidence events revealed, thanks to exon-exon junction probes, specific splicing events (Table 2). For example *AKT3* je7_e8, *HER1/EGFR* je16_e19 or *HIF1A* je10_e11 junction-specific events would have been undetected on Affymetrix™ arrays. In addition, selecting only the high confidence events, the regulations observed through the chip analysis were confirmed by quantitative RT-PCR, emphasizing the robustness of both the technical and the analytical tools used in this study. Nevertheless, we anticipate that RNA-Seq methodologies will probably soon be another, reliable, means for characterizing AS throughout the transcriptome [30,31].

We are aware of only one study that used a designed chip to analyze the occurrence of splicing variants which, in that case, corresponded to AS events from a single gene, *CIZ1*, encoding a Cip1-interacting zinc finger protein [32]. This approach led to the identification of a splice variant that may be specific for pediatric cancer. There is an absolute need for predictive biomarkers of therapeutic responses, especially targeted anticancer therapies, as many patients do not respond or acquire resistance. For instance, VEGF-A isoforms may not respond identically to anti-VEGF-A mAbs (bevacizumab). In fact, the co-occurrence of both pro-angiogenic (VEGF-A_{xxx}) and anti-angiogenic (VEGF-A_{xxx}b) splice isoforms might restrict the therapeutic response [33-37]. In addition, the occurrence of soluble EGFR isoforms, as detected in meningiomas [38], presumably unresponsive to tyrosine kinase inhibitor therapy, might also dampen the therapeutic response. Furthermore, an exon 4-lacking EGFR variant mRNA was associated with an increased metastatic potential, a molecular event that would likely have been detected with our splice-sensitive microarray [39]. Hence, in addition to providing a comprehensive picture of splicing events and potential therapy response, our chip could also help predicting clinical outcome, based on the detection of pro-metastatic mRNA species. Nevertheless, beyond the concept, more predictive studies should be performed to make our splice-screening methodology an efficient therapy selecting option.

We showed that SRSF2 has an effect on transcriptional regulation and on AS of several genes analyzed in this study. Notably, SRSF2 over-expression modified *HER1/*

EGFR and *VEGFA* expression in H358 lung cancer cells. Using patient-derived material, we observed that strong SRSF2 over-expression in NSCLC is associated with splicing alterations of the *HER1/EGFR* and *VEGFA* transcripts, as predicted from the results in the SRSF2-over-expressing H358 lung cancer cell line. In addition, *HER1/EGFR* splicing events have also been identified in lung adenocarcinomas [40], lending support to our results. The observation that the increase in SRSF2 protein level induced massive procaspase-3 cleavage when associated with gefitinib in H358 cells, which express wild-type and non amplified EGFR protein, may be particularly relevant for patients with lung adenocarcinomas without EGFR mutations, as one of the challenges is to understand why only some of them respond to EGFR tyrosine kinase inhibitors.

The expression level of *HER1* mRNA, measured through analysis of the 44 k Agilent™ chip, and the western blotting analysis of the protein, showed a good correlation in response to SRSF2 over-expression. In this specific case, use of the custom 15 k chip would not have been more predictive. Nevertheless, it is doubtless that AS, analyzed globally for all genes from the chip, will provide a lot more information on both transcript abundance and structure, allowing defining a prognostic indicator of response to antibody-based therapy [41]. An important challenge will be to develop specific antibodies to detect full length or modified proteins encoded by AS-derived transcripts. Alternatively, mass spectrometry proteomics could be used to identify and quantify such proteins [42]. The custom chip analysis could thus ideally supplement immunology- or proteomics-based approaches aimed at looking for the expression of protein targets. Our DNA gene chip could also be used to analyze the effect of other triggers, such as over-expression or silencing of other splice-modifying proteins, or treatment with drugs, especially anticancer drugs, which can profoundly affect pre-mRNA splicing [3,43].

Conclusion

Our results describe, for the first time, the design and validation of a custom splice-sensitive microarray to detect AS events occurring in genes involved in the response to targeted anticancer therapies. Such an experimental setup could help clinicians choose anticancer drugs depending on the tumor expression of gene targets with proficient mRNA structures.

Table 5 Comparison of gene coverage between the custom gene chip and the Affymetrix™ Exon Array

Gene	Custom array (present study)		Affymetrix™ Exon array	
	Nb probes (exonic/junction)	Average probe length (bp)	Nb probes (exonic/junction)	Average probe length (bp)
HIF1A	123 (85/38)	42.4	80 (80/0)	25.0
VEGFA	90 (64/26)	42.3	60 (60/0)	25.0

The numbers of probes and their average length are shown for both the HIF1A and VEGFA genes.

Methods

Custom microarray design

A custom microarray was designed taking advantage on the 15 k Whole Human Genome microarray, available from Agilent™ (Agilent, Massy, France). Among the Agilent™ probes initially loaded on the chip, 11,881 (Additional file 8: Figure S2) were substituted by custom oligonucleotides, corresponding to known and predicted exons, introns and junctions of 16 selected genes, among which there were members of the AKT (*AKT1*, *AKT2*, *AKT3*), HER (*HER1/EGFR*, *HER2*, *HER3*, *HER4*), PIK3 (*PIK3CA*, *PIK3R1*, *PIK3R2*) and VEGF (*VEGFA*, *VEGFB*, *VEGFC*, *VEGFD*) families, but also *HIF1A* and *PIR*. On the microarray, the majority (60%) of custom probes had a length of 40 bp; some were shorter (down to 22 bp; 8%); others were longer (up to 50 bp; 26%), which was mostly the case of the probes for exon-exon junctions. This was especially important to insure a good detection of alternative 5' and 3' splice sites, *i.e.* alternative exon boundaries. Each custom probe length was adjusted to 60 bp with linker addition. The other 3,863 probes on the microarray corresponded to replicates of commercial Agilent™ probes (genes or controls). As a whole, the expression of 1,967 distinct genes can be analyzed with our chip.

Cell culture and RNA extraction

The H358 human lung adenocarcinoma cell line was cultured as described previously [44]. The H358/Tet-On/SRSF2 inducible clone, conditionally over-expressing the SRSF2 splicing factor under the control of a Tet-responsive promoter, has been described previously [44,45]. SRSF2 over-expression was induced upon 24 hours treatment with 1 µg/mL doxycycline (Additional file 9: Figure S3). Gefitinib was added to the cells at the indicated final concentrations for 24 hours. Total RNA was isolated using the Trizol reagent (Invitrogen, Cergy-Pontoise, France), according to the manufacturer's instructions. RNA purity and integrity were determined by measuring the optical density ratio (A260/A280) and the RNA integrity number (RIN) using the RNA 6000 Nano LabChip (Agilent™) and the 2100 Bioanalyzer (Agilent™). Only RNA samples with a 28S/18S ratio > 1.0 and RIN ≥ 7.0 were used for microarray analyses.

Plasmid transfection and minigene analysis

An E1A reporter minigene-containing plasmid (pXJ41-E1A) to study the effect of splice modifier proteins was used to further validate the effect of SRSF2 protein over-expression. The plasmid was transfected using Lipofectamine 2000 (Invitrogen). Cells were harvested 24 hours after transfection, and total RNA was extracted using the RNeasy Mini kit (Qiagen, Courtabœuf, France), according to the manufacturer's instructions. The RNAs (200 ng) were further used for first-strand cDNA

synthesis with the High-Capacity cDNA Reverse Transcription kit (Applied Biosystems, Courtabœuf, France). For the detection of E1A splice variants, PCR amplification was performed using primers 5'-TTT-GGA-CCA-GCT-GAT-CGA-AG-3' and 5'-AAG-CTT-GGG-CTG-CAG-GTC-GA-3', and PCR products were analyzed by agarose gel electrophoresis.

Microarray hybridization

Analyses of the H358/Tet-On/SRSF2 mRNA content were performed on both the 15 k custom microarray and the 44 k Whole Human Genome microarray (Agilent™) that contains roughly 41,000 probes, providing full coverage of human transcripts. Double-stranded cDNA was synthesized from 500 ng of total RNA using the Quick Amp Labeling kit, One-color, as instructed by the manufacturer (Agilent™). Labeling with cyanine3-CTP, fragmentation of cRNA, hybridization and washing were performed according to the manufacturer's instructions. The microarrays were scanned and the data were extracted with the Agilent™ Feature Extraction Software.

Gene expression analysis

The bioinformatics analysis of the 15 k custom microarray data and the comparison of 15 k chip results with 44 k commercial chip results were performed by GenoSplice technology™. Concerning the 15 k custom microarray data analysis, data were normalized using median normalization based on Agilent™ control genes. Gene expression level was assessed using constitutive probes only (*i.e.*, probes targeting regions that are not known to be alternative regions). For each gene of interest, all possible splicing patterns were defined and analyzed. All types of alternative events can be analyzed: alternative first exons, alternative terminal exons, cassette exons, mutually exclusive exons, alternative 5' donor splice sites, alternative 3' acceptor splice sites, and intron retentions. Analyses were performed using unpaired Student's *t*-test on the splicing-index as previously described [46,47]. Results were considered statistically significant for unadjusted P-values ≤ 0.05 and fold-changes ≥ 1.5. After bioinformatics analysis of microarray data, a manual inspection using the GenoSplice EASANA™ interface was conducted to select high-confidence events. An alternative 44 k bioinformatics analysis was carried out. Raw gene expression data were imported into the GeneSpring GX 11.0.2 software program (Agilent™). Genes with missing values in more than 25% of the samples were excluded from the analysis. A 2-fold cut-off difference was applied to select the up- and down-regulated genes (P-value ≤ 0.05 by *t*-test with Benjamini-Hochberg false discovery rate).

Real-time polymerase chain reaction analysis

Regulation events detected in the 15 k custom and 44 k commercial microarrays were analyzed by quantitative RT-PCR using RNA isolated from cell preparations separate from those originally used for microarray hybridization. Reverse transcription was performed as instructed by the manufacturer (Applied Biosystems), as described previously, and quantitative RT-PCR was conducted using the SYBR GREEN PCR Master Mix (Applied Biosystems), according to the manufacturer's instructions, with an ABI 7300 real-time PCR system (Applied Biosystems). All determinations were performed in duplicate, normalized against *beta*-2-microglobulin or *GAPDH* as internal control genes. These reference transcripts were found to be stable when surveyed in several cell culture systems (data not shown). The results were expressed as the relative gene expression using the $\Delta\Delta C_t$ method [48]. The fold-change was also calculated comparing to a reference event. The sequences of the primers used for the 15 k custom microarray validation are presented in Additional file 10: Table S7.

Protein extraction and western blotting analysis

The antibodies used in this study included anti-SRSF2 (4 F11) from Euromedex, anti-EGFR (31G7) from Invitrogen, anti-HER1/EGFR (D38B1) and anti-P-HER1/EGFR (Tyr1068) (D7A5) from Cell Signaling. For immunoblotting, cells were lysed in RIPA buffer [150 mM NaCl, 50 mM Tris HCl pH 8, 0.1% SDS, 1% Nonidet P40, 0.5% Na deoxycholate, 0.1 mM PMSF, 2.5 μ g/mL pepstatin, 10 μ g/mL aprotinin, 5 μ g/mL leupeptin, 0.2 mM Na_3VO_4] for 30 minutes on ice and pelleted. Protein concentration was determined using the Biorad DC protein assay. Proteins (40–80 μ g) were then separated in 10% SDS-PAGE gels and electroblotted onto PVDF membranes. Membranes were incubated overnight at +4°C with primary antibodies and proteins were detected using horseradish peroxidase-conjugated goat antibodies (Jackson ImmunoResearch Laboratories, West Grove, PA, USA). After washing, the blots were revealed using the ECL chemiluminescence method (Amersham, Les Ulis, France). Tubulin was used as a loading control.

Human samples

Tissue samples were collected from resection of lung tumors, and stored for scientific research in a biological resource repository (Centre de Ressources Biologiques, CHU Albert Michallon, Grenoble Hospital). National ethical guidelines were followed. All patients enrolled provided written informed consent. Tissue banking and research conduct was approved by the Ministry of Research (approval AC-2010-1129) and by the regional IRB

(CPP 5 Sud Est). Protein and RNA samples were isolated and analysed as described above.

Additional files

Additional file 1: Figure S1. E1A splicing assay in response to SRSF2 over-expression. Following transient cell transfection with a SRSF2 expression plasmid, E1A splice-derived PCR products were electrophoresed through a 2% agarose gel and stained with ethidium bromide. The characteristic PCR products (9S-13S) are shown.

Additional file 2: Table S1. Deregulated genes on the 44k AgilentTM microarray in H358 SRSF2-over-expressing cells. Significantly down- and up-regulated genes in SRSF2-over-expressing H358 lung cancer cells in comparison to H358 control cells are listed (≥ 2.0 FC, P-value ≤ 0.05 by t-test with FDR).

Additional file 3: Table S2. Regulation of the 16 selected genes on the 44k AgilentTM microarray in SRSF2-over-expressing H358 cells. The results for the 8 deregulated genes in SRSF2-over-expressing H358 lung cancer cells in comparison to H358 control cells on the 44k microarrays are shown (≥ 1.1 FC, P-value ≤ 0.05 by t-test with FDR). The 44k microarray results for the 8 deregulated genes showed a good concordance with the 15k custom microarray results.

Additional file 4: Table S3. Labeling efficiency for hybridization of the 15k custom microarray. The labeled cRNA yield and specific activity of cyanine3 are shown for each of the three labeling experiments performed. The cRNA yield should be superior to 1.65 μ g, and the specific activity superior to 9.0 pmol cyanine3 per μ g cRNA. The number of 15k replicates using Quick Amp labeling was 4 for each condition (control or SRSF2 over-expression), and the number of 44k replicates was 6 (i.e. 2 for each of the three labeling) for each condition.

Additional file 5: Table S4. Comparison of the 15k custom and 44k AgilentTM microarray results. The results are shown for the AgilentTM probes present on both chips: 313 probes were deregulated in SRSF2-over-expressing H358 lung cancer cells in comparison to H358 control cells on the 15k custom chip (≥ 1.5 FC, P-value ≤ 0.05), and 310 had the same type of regulation, considering statistically relevant and not statistically relevant regulations on the 44k chip (same type of regulation = 1; other type of regulation = 0).

Additional file 6: Table S5. Supporting evidences that confirmed the regulation of some probe sets in SRSF2-over-expressing H358 lung cancer cells in comparison to H358 control cells is presented.

Additional file 7: Table S6. Quantitative RT-PCR validation. Common regulation events between the 15k custom and 44k AgilentTM microarrays were validated by quantitative RT-PCR in SRSF2-over-expressing H358 lung cancer cells in comparison to H358 control cells. Relative mRNA levels were normalized to that of *GAPDH*.

Additional file 8: Figure S2. Design of the custom 15k gene chip. The chip was designed on the backbone of the AgilentTM 15k whole-genome microarray. The majority of the probes correspond to custom oligonucleotides, i.e. to both known and predictable sequences of exons, introns and junctions of 16 genes selected for their biological interest in the response to targeted anticancer therapies: *AKT1-3*, *HER1-4*, *HIF1A*, *PIK3CA*, *PIK3R1-2*, *VEGFA-D* and *PIR*. The resolution of the custom microarray was decreased in comparison to the Human Exon 1.0 ST array (AffymetrixTM) from 5 million to 12,000 probes, but the number of probes per gene was largely increased, from an average of 45 to an average of 185 probes per gene. The expression of 1,967 distinct genes can also be analyzed thanks to commercial AgilentTM probes.

Additional file 9: Figure S3. Western blot analysis of SRSF2 expression. SRSF2 protein level was analyzed in H358/Tet-On/SRSF2 inducible clone by western blotting with the mAb104 monoclonal antibody that recognizes several phosphorylated SR proteins (SRSF2-6). SRSF2 mRNA level was also analyzed by quantitative RT-PCR (data not shown). Relative mRNA level was normalized to that of *GAPDH*. An 8-fold over-expression

of SRSF2 mRNA was observed in SRSF2-over-expressing lung cancer cells in comparison to control cells.

Additional file 10: Table S7. Primers for validation. The sequences of the primers used for the 15k custom microarray validation are presented.

Abbreviations

AS: Alternative pre-mRNA splicing; FC: Fold-change; FDR: Benjamini-Hochberg false discovery rate; mAbs: monoclonal antibodies; NMD: nonsense mediated decay; NSCLC: Non-small cell lung carcinoma.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

MP performed the RT-PCR validation of microarray hybridization results, performed the E1A plasmid transfection and RT-PCR analysis, and drafted the manuscript. BS conducted the microarray experiments. BE developed the SRSF2-over-expressing lung cancer cells, and performed the western blotting experiments. PDLG designed the 15 k custom microarray, and performed the bioinformatics analysis of the data. LC coordinated the study, assisted with the design of experiments, and drafted the manuscript. All authors read and approved the final manuscript.

Acknowledgements

We thank Dr. Pascal Loyer for his gift of the E1A plasmid minigene, and Dr. Sandrine Jacolot for her help with analysis of the microarray data. MP was recipient of a fellowship from the Région Bretagne (ARED). This work was supported by the INSERM, the Université de Bretagne Occidentale, the Ligue Contre le Cancer (Comité du Finistère), and the BioIntelligence program.

Author details

¹UMR INSERM U1078-UBO, Equipe ECLA, Faculté de Médecine, 22 Avenue Camille Desmoulins, 29200 Brest, France. ²Centre de Recherche INSERM U823, Université Joseph Fourier, Equipe 2 Bases Moléculaires de la Progression des Cancers du Poumon, Institut Albert Bonniot, Domaine de la Merci, Rond-Point de la Chantourne, 38706 La Tronche Cedex, France. ³IUH, Centre Hayem, 1 Avenue Claude Vellefaux, 75010 Paris, France.

Received: 30 August 2013 Accepted: 9 January 2014

Published: 15 January 2014

References

1. Wang ET, Sandberg R, Luo S, Khrebtkova I, Zhang L, Mayr C, Kingsmore SF, Schroth GP, Burge CB: **Alternative isoform regulation in human tissue transcriptomes.** *Nature* 2008, **456**:470–476.
2. Nilsen TW, Graveley BR: **Expansion of the eukaryotic proteome by alternative splicing.** *Nature* 2010, **463**:457–463.
3. Dutertre M, Sanchez G, De Cian M-C, Barbier J, Dardenne E, Gratadou L, Dujardin G, Le Jossic-Corcus C, Corcos L, Auboeuf D: **Cotranscriptional exon skipping in the genotoxic stress response.** *Nat Struct Mol Biol* 2010, **17**:1358–1366.
4. Hallegger M, Llorian M, Smith CWJ: **Alternative splicing: global insights.** *FEBS J* 2010, **277**:856–866.
5. David CJ, Manley JL: **Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged.** *Genes Dev* 2010, **24**:2343–2364.
6. Akgul C, Moulding DA, Edwards SW: **Alternative splicing of Bcl-2-related genes: functional consequences and potential therapeutic applications.** *Cell Mol Life Sci* 2004, **61**:2189–2199.
7. Miura K, Fujibuchi W, Unno M: **Splice variants in apoptotic pathway.** *Exp Oncol* 2012, **34**:212–217.
8. Schwerk C, Schulze-Osthoff K: **Regulation of apoptosis by alternative pre-mRNA splicing.** *Mol Cell* 2005, **19**:1–13.
9. Maquat LE: **Nonsense-mediated mRNA decay: splicing, translation and mRNP dynamics.** *Nat Rev Mol Cell Biol* 2004, **5**:89–99.
10. Isken O, Maquat LE: **The multiple lives of NMD factors: balancing roles in gene and genome regulation.** *Nat Rev Genet* 2008, **9**:699–712.
11. Gardina PJ, Clark TA, Shimada B, Staples MK, Yang Q, Veitch J, Schweitzer A, Awad T, Sugnet C, Dee S, *et al*: **Alternative splicing and differential gene expression in colon cancer detected by a whole genome exon array.** *BMC Genomics* 2006, **7**:325.
12. Mojica W, Hawthorn L: **Normal colon epithelium: a dataset for the analysis of gene expression and alternative splicing events in colon disease.** *BMC Genomics* 2010, **11**:5.
13. Xuan J, Yu Y, Qing T, Guo L, Shi L: **Next-generation sequencing in the clinic: promises and challenges.** *Cancer Lett* 2012, **340**:248–295.
14. Wang Z, Gerstein M, Snyder M: **RNA-Seq: a revolutionary tool for transcriptomics.** *Nat Rev Genet* 2009, **10**:57–63.
15. Mutz K-O, Heilkenbrinker A, Lönne M, Walter J-G, Stahl F: **Transcriptome analysis using next-generation sequencing.** *Curr Opin Biotechnol* 2013, **24**:22–30.
16. Lindner R, Friedel CC: **A comprehensive evaluation of alignment algorithms in the context of RNA-Seq.** *PLoS ONE* 2012, **7**:e52403.
17. Trapnell C, Hendrickson DG, Sauvageau M, Goff L, Rinn JL, Pachter L: **Differential analysis of gene regulation at transcript resolution with RNA-seq.** *Nat Biotechnol* 2012, **31**:46–53.
18. Xu W, Seok J, Mindrinos MN, Schweitzer AC, Jiang H, Wilhelmy J, Clark TA, Kapur K, Xing Y, Faham M, *et al*: **Human transcriptome array for high-throughput clinical studies.** *Proc Natl Acad Sci* 2011, **108**:3707–3712.
19. Glas AM, Floore A, Delahaye LJM, Witteveen AT, Pover RCF, Bakx N, Lahti-Domenici JST, Bruinsma TJ, Warmoes MO, Bernards R, *et al*: **Converting a breast cancer microarray signature into a high-throughput diagnostic test.** *BMC Genomics* 2006, **7**:278.
20. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA: **Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.** *N Engl J Med* 2005, **353**:1673–1684.
21. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C: **Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.** *N Engl J Med* 2005, **353**:1659–1672.
22. Muller YA, Chen Y, Christinger HW, Li B, Cunningham BC, Lowman HB, de Vos AM: **VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 Å resolution and mutational analysis of the interface.** *Structure* 1998, **6**:1153–1167.
23. Robinson CJ, Stringer SE: **The splice variants of vascular endothelial growth factor (VEGF) and their receptors.** *J Cell Sci* 2001, **114**:853–865.
24. Bates DO, Cui T-G, Doughty JM, Winkler M, Sugiono M, Shields JD, Peat D, Gillatt D, Harper SJ: **VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma.** *Cancer Res* 2002, **62**:4123–4131.
25. Ladomery MR, Harper SJ, Bates DO: **Alternative splicing in angiogenesis: the vascular endothelial growth factor paradigm.** *Cancer Lett* 2007, **249**:133–142.
26. Merdzhanova G, Gout S, Keramidias M, Edmond V, Coll JL, Brambilla C, Brambilla E, Gazzeri S, Eymin B: **The transcription factor E2F1 and the SR protein SC35 control the ratio of pro-angiogenic versus antiangiogenic isoforms of vascular endothelial growth factor-A to inhibit neovascularization in vivo.** *Oncogene* 2010, **29**:5392–5403.
27. Lin S, Coutinho-Mansfield G, Wang D, Pandit S, Fu X-D: **The splicing factor SC35 has an active role in transcriptional elongation.** *Nat Struct Mol Biol* 2008, **15**:819–826.
28. Gout S, Brambilla E, Boudria A, Drissi R, Lantuejoul S, Gazzeri S, Eymin B: **Abnormal expression of the pre-mRNA splicing regulators SRSF1, SRSF2, SRPK1 and SRPK2 in non small cell lung carcinoma.** *PLoS ONE* 2012, **7**:e46539.
29. Wang J, Manley JL: **Overexpression of the SR proteins ASF/SF2 and SC35 influences alternative splicing in vivo in diverse ways.** *RNA* 1995, **1**:335–346.
30. Wang X, Cairns MJ: **Gene set enrichment analysis of RNA-Seq data: integrating differential expression and splicing.** *BMC Bioinforma* 2013, **14**:S16.
31. Ma X, Zhang X: **NURD: an implementation of a new method to estimate isoform expression from non-uniform RNA-seq data.** *BMC Bioinforma* 2013, **14**:220.
32. Rahman FA, Aziz N, Coverley D: **Differential detection of alternatively spliced variants of Ciz1 in normal and cancer cells using a custom exon-junction microarray.** *BMC Cancer* 2010, **10**:482.
33. Bates DO, Harper SJ: **Therapeutic potential of inhibitory VEGF splice variants.** *Future Oncol* 2005, **1**:467–473.
34. Harper SJ, Bates DO: **VEGF-A splicing: the key to anti-angiogenic therapeutics?** *Nat Rev Cancer* 2008, **8**:880–887.
35. Nowak DG, Amin EM, Rennel ES, Hoareau-Aveilla C, Gammons M, Damodoran G, Hagiwara M, Harper SJ, Woolard J, Ladomery MR, Bates DO:

- Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis. *J Biol Chem* 2010, **285**:5532–5540.
36. Qiu Y, Hoareau-Aveilla C, Oltean S, Harper SJ, Bates DO: **The anti-angiogenic isoforms of VEGF in health and disease.** *Biochem Soc Trans* 2009, **37**:1207–1213.
 37. Hilmi C, Guyot M, Pages G: **VEGF spliced variants: possible role of anti-angiogenesis therapy.** *J Nucleic Acids* 2012, **2012**:162692.
 38. Guillaudeau A, Durand K, Bessette B, Chaunavel A, Pommepuy I, Progetti F, Robert S, Caire F, Rabinovitch-Chable H, Labrousse F: **EGFR soluble isoforms and their transcripts are expressed in meningiomas.** *PLoS One* 2012, **7**:e37204.
 39. Wang H, Zhou M, Shi B, Zhang Q, Jiang H, Sun Y, Liu J, Zhou K, Yao M, Gu J, *et al*: **Identification of an exon 4-deletion variant of epidermal growth factor receptor with increased metastasis-promoting capacity.** *Neoplasia* 2011, **13**:461–471.
 40. Imielinski M, Berger Alice H, Hammerman Peter S, Hernandez B, Pugh Trevor J, Hodis E, Cho J, Suh J, Capelletti M, Sivachenko A, *et al*: **Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.** *Cell* 2012, **150**:1107–1120.
 41. Varey AHR, Rennel ES, Qiu Y, Bevan HS, Perrin RM, Raffy S, Dixon AR, Paraskeva C, Zaccaro O, Hassan AB, *et al*: **VEGF165b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy.** *Br J Cancer* 2008, **98**:1366–1379.
 42. Lagarrigue M, Alexandrov T, Dieuset G, Perrin A, Lavigne R, Baulac S, Thiele H, Martin B, Pineau C: **New analysis workflow for MALDI imaging mass spectrometry: application to the discovery and identification of potential markers of childhood absence epilepsy.** *J Proteome Res* 2012, **11**:5453–5463.
 43. Solier S, Lansiaux A, Logette E, Wu J, Soret J, Tazi J, Bailly C, Desoche L, Solary E, Corcos L: **Topoisomerase I and II inhibitors control caspase-2 Pre-Messenger RNA splicing in human cells.** *Mol Cancer Res* 2004, **2**:53–61.
 44. Salon C, Eymin B, Micheau O, Chaperot L, Plumas J, Brambilla C, Brambilla E, Gazzeri S: **E2F1 induces apoptosis and sensitizes human lung adenocarcinoma cells to death-receptor-mediated apoptosis through specific downregulation of c-FLIPshort.** *Cell Death Differ* 2006, **13**:260–272.
 45. Salon C, Merdzhanova G, Brambilla C, Brambilla E, Gazzeri S, Eymin B: **E2F1, Skp2 and cyclin E oncoproteins are upregulated and directly correlated in high-grade neuroendocrine lung tumors.** *Oncogene* 2007, **26**:6927–6936.
 46. Gandoura S, Weiss E, Rautou P-E, Fasseu M, Gustot T, Lemoine F, Hurtado-Nedelec M, Hego C, Vadrot N, Elkrief L: **Gene-and exon-expression profiling reveals an extensive LPS-induced response in immune cells in patients with cirrhosis.** *J Hepatol* 2013, **58**:936–948.
 47. Wang E, Aslanzadeh V, Papa F, Zhu H, de la Grange P, Cambi F: **Global profiling of alternative splicing events and gene expression regulated by hnRNP/F.** *PLoS ONE* 2012, **7**:e51266.
 48. Livak KJ, Schmittgen TD: **Analysis of relative gene expression data using real-time quantitative PCR and the 2 – ΔΔCT method.** *Methods* 2001, **25**:402–408.

doi:10.1186/1476-4598-13-9

Cite this article as: Pesson *et al*: A dedicated microarray for in-depth analysis of pre-mRNA splicing events: application to the study of genes involved in the response to targeted anticancer therapies. *Molecular Cancer* 2014 **13**:9.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

